Objective: The treatment of bipolar depression is a significant clinical problem that remains understudied. The role for antidepressant (AD) agents vs. mood stabilizers has been particularly problematic to ascertain.
Method: Detailed life charting data from 42 patients with 67 depressive episodes were reviewed. Response rates and rates of switch into mania were compared based on the preceding mood state and on whether an AD or mood stabilizing (MS) agent was added following onset of depression.
Results: Patients who became depressed following a period of euthymia were more likely to respond to treatment (62.5%) than patients who became depressed following a period of mania or hypomania (27.9%). The ratio of response to switch for previously euthymic patients was particularly favorable.
Conclusion: Mood state prior to onset of depression in bipolar disorder appears to be an important clinical variable that may guide both choice of treatment administered and expectation of outcome to treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1034/j.1600-0447.2002.01116.x | DOI Listing |
Front Psychol
December 2024
Department of Computer Science and Engineering, University of Notre Dame, Notre Dame, IN, United States.
Introduction: While the fact that visual stimuli synthesized by Artificial Neural Networks (ANN) may evoke emotional reactions is documented, the precise mechanisms that connect the strength and type of such reactions with the ways of how ANNs are used to synthesize visual stimuli are yet to be discovered. Understanding these mechanisms allows for designing methods that synthesize images attenuating or enhancing selected emotional states, which may provide unobtrusive and widely-applicable treatment of mental dysfunctions and disorders.
Methods: The Convolutional Neural Network (CNN), a type of ANN used in computer vision tasks which models the ways humans solve visual tasks, was applied to synthesize ("dream" or "hallucinate") images with no semantic content to maximize activations of neurons in precisely-selected layers in the CNN.
Front Immunol
December 2024
Tumor Vaccine and Biotechnology Branch, Office of Cellular Therapy and Human Tissues, Office of Therapeutic Products, Center for Biologics Evaluation and Research, United States Food and Drug Administration (U.S. FDA), Silver Spring, MD, United States.
Introduction: CAR-T cell therapy is associated with life-threatening inflammatory toxicities, partly due to the activation and secretion of inflammatory cytokines by bystander myeloid cells (BMCs). However, due to limited clinical data, it is unclear whether CAR-NK cells cause similar toxicities.
Methods: We characterized the soluble factors (SFs) released by activated human CAR-T and CAR-NK cells and assessed their role in BMC activation (BMCA).
Front Immunol
December 2024
Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Introduction: T cell activation requires T cell receptor (TCR) engagement by its specific ligand. This interaction initiates a series of proximal events including tyrosine phosphorylation of the CD3 and TCRζ chains, recruitment, and activation of the protein tyrosine kinases Lck and ZAP70, followed by recruitment of adapter and signaling proteins. CD28 co-stimulation is also required to generate a functional immune response.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!